Investigation of ovarian cancer associated sialylation changes in N-linked glycopeptides by quantitative proteomics.

ABSTRACT:

Background

In approximately 80% of patients, ovarian cancer is diagnosed when the patient is already in the advanced stages of the disease. CA125 is currently used as the marker for ovarian cancer; however, it lacks specificity and sensitivity for detecting early stage disease. There is a critical unmet need for sensitive and specific routine screening tests for early diagnosis that can reduce ovarian cancer lethality by reliably detecting the disease at its earliest and treatable stages.

Results

In this study, we investigated the N-linked sialylated glycopeptides in serum samples from healthy and ovarian cancer patients using Lectin-directed Tandem Labeling (LTL) and iTRAQ quantitative proteomics methods. We identified 45 N-linked sialylated glycopeptides containing 46 glyc

SUBMITTER: Shetty V 

PROVIDER: S-EPMC3488482 | biostudies-literature | 2012 Aug

REPOSITORIES: biostudies-literature